IP Library Granted Patent US 12,318,612
Granted Patent B2
US 12,318,612 · App. 18/125,608 · Granted Jun 3, 2025

Electrotherapy and neurostimulation medical device apparatus and method

Inventors: Bradford Siff (Norwalk, CT); John Carter (Belle Harbor, NY)
Assignee: BioWave Corporation
A61N1/36021A61N1/36031A61N1/36034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,318,612
App. No.
18/125,608
Granted
Jun 3, 2025
Kind
B2
Abstract

A method and apparatus are disclosed for providing therapeutic electric current to a treatment site of a patient. The steps of the method comprise generating a first and second signal having a frequency difference between 1 Hz and 300 Hz, wherein each signal has a frequency of at least 1 KHz and are amplified by Class D switching amplifiers, minimizing the DC component of the first and second signals using balanced amplifiers; operatively coupling a first electrode of at least one pair of electrodes to a patient's body on or beneath a first epidermal or mucous membrane surface; operatively coupling a second electrode of at least one pair of electrodes to a patient's body on or beneath a second epidermal or mucous membrane surface; forming a therapeutic signal configured to reduce pain at a treatment site by simultaneously sending a first signal from the first electrode to the second electrode and sending a second signal from a second electrode to the first electrode, and then simultaneously sending the first signal from the second electrode back to the first electrode and the second signal from the first electrode back to the second electrode, wherein the first and second signals are linearly independent off phase alternating current signals; and adjusting the therapeutic signal utilizing a feedback system based on impedance changes within the patient's body.

Claims (47)

1. An electrotherapy system, comprising:

an electrotherapy device comprising:

a female port disposed on the electrotherapy device and configured to receive a male connector;

a subsystem configured to generate a first signal and a second signal having a frequency difference between 1 Hz and 300 Hz, wherein the first signal and the second signal have a base frequency of at least 200 Hz, and wherein the first signal and the second signal are linearly independent off phase alternating current signals that form a therapeutic signal;

class D switching amplifiers configured to amplify the first signal and the second signal, and configured to minimize a direct current (DC) component of the first signal and the second signal;

a feedback system configured to adjust the therapeutic signal based on an impedance change within a patient's body; and

a cable disposed between the male connector and two electrodes, wherein the two electrodes comprise a first electrode and a second electrode that are configured to be coupled to the patient's body, wherein the therapeutic signal is configured to reduce pain at a treatment site by sending a first signal from the first electrode to the second electrode and sending a second signal from the second electrode to the first electrode, and then simultaneously sending the first signal from the second electrode back to the first electrode and the second signal from the first electrode back to the second electrode.

2. The electrotherapy system of claim 1 , wherein the first signal and the second signal are summed before being amplified.

3. The electrotherapy system of claim 1 , wherein the therapeutic signal is a linear combination of the first signal and the second signal.

4. The electrotherapy system of claim 3 , wherein the therapeutic signal is a sum of the first signal and the second signal.

5. The electrotherapy system of claim 1 , wherein the feedback system is configured to monitor at least one of a voltage or a current associated with the impedance of a patient's body and further configured to control the therapeutic signal in response to the voltage or the current.

6. The electrotherapy system of claim 5 , wherein the feedback system utilizes software configured to determine whether a change in the therapeutic signal is required, based at least in part on at least one of the voltage and the current.

7. The electrotherapy system of claim 1 , wherein the therapeutic signal is controlled so as to maintain a monitored voltage at a constant voltage level.

8. The electrotherapy system of claim 1 , wherein the base frequency of the first signal and the second signal is between 200 Hz and 500 KHz.

9. The electrotherapy system of claim 1 , wherein the feedback system comprises:

a resistor or a current transformer that monitors a current through the patient's body;

an amplifier for differentially detecting a voltage developed by said current passing through the resistor;

a gain block for further amplifying a detected voltage;

a buffered attenuator for sampling the voltage across the two electrodes and setting the voltage's value to within a predetermined range of an analog-to-digital (ADC) circuit to which the voltage is to be input;

an analog multiplexer having as a first input thereto an output of the gain block and having as a second input thereto an output of the buffered attenuator, the analog multiplexer configured to selectively output either the first input or the second input, based on a signal from a central processing unit;

a root mean square (RMS) to DC converter having input thereto for an output of the analog multiplexer, and being configured to output a DC level approximately equal to the RMS value of an applied signal;

an analog-to-digital converter configured to convert an analog output of the RMS to DC converter into a digital signal; and

a digital attenuator configured to change the digital signal, as required by the feedback system.

10. The electrotherapy system of claim 1 , further comprising a timer configured to monitor a treatment time set by an operator of the electrotherapy device when the electrotherapy device is initialized.

11. An electrotherapy system, comprising:

an electrotherapy device comprising:

a female port disposed on the electrotherapy device and configured to receive a male connector;

a subsystem configured to generate a first signal and a second signal having a frequency difference between 1 Hz and 300 Hz, wherein the first signal and the second signal have a base frequency between 1 KHz and 500 KHz, and wherein the first signal and the second signal are linearly independent off phase alternating current signals that form a therapeutic signal;

class D switching amplifiers configured to amplify the first signal and the second signal, and configured to minimize a direct current (DC) component of the first signal and the second signal;

a cable disposed between the male connector and two electrodes, wherein the two electrodes comprise a first electrode and a second electrode that are configured to be coupled to a patient's body, wherein the therapeutic signal is configured to reduce pain at a treatment site by sending a first signal from the first electrode to the second electrode and sending a second signal from the second electrode to the first electrode, and then simultaneously sending the first signal from the second electrode back to the first electrode and the second signal from the first electrode back to the second electrode.

12. The electrotherapy system of claim 11 , wherein the first signal and the second signal are summed before being amplified.

13. The electrotherapy system of claim 11 , wherein the therapeutic signal is a linear combination of the first signal and the second signal.

14. The electrotherapy system of claim 13 , wherein the therapeutic signal is a sum of the first signal and the second signal.

15. The electrotherapy system of claim 11 , further comprising a feedback system configured to adjust the therapeutic signal based on an impedance change within the patient's body.

16. The electrotherapy system of claim 15 , wherein the feedback system is configured to monitor at least one of a voltage or a current associated with an impedance of the patient's body and control the therapeutic signal in response to a change in the voltage or the current.

17. The electrotherapy system of claim 16 , wherein the therapeutic signal is controlled so as to maintain the monitored voltage at a constant voltage level.

18. The electrotherapy system of claim 17 , wherein the feedback system utilizes software configured to determine whether a change in the therapeutic signal is required, based at least in part on at least one of the voltage and the current.

19. The electrotherapy system of claim 18 , wherein the feedback system comprises:

a resistor or a current transformer that monitors a current through the patient's body;

an amplifier for differentially detecting a voltage developed by the current passing through the resistor;

a gain block for further amplifying a detected voltage;

a buffered attenuator for sampling the voltage across the two electrodes and setting the voltage's value to within a predetermined range of an analog-to-digital (ADC) circuit to which the voltage is to be input;

an analog multiplexer having as a first input thereto an output of the gain block and having as a second input thereto an output of buffered attenuator, the analog multiplexer configured to selectively output either the first input or the second input, based on a signal from a central processing unit;

an root mean square (RMS) to DC converter having input thereto an output of the analog multiplexer, and being configured to output a DC level approximately equal to the RMS value of an applied signal;

an analog-to-digital converter configured to convert an analog output of the RMS to DC converter into a digital signal; and

a digital attenuator configured to change the digital signal, as required by the feedback system.

20. The electrotherapy system of claim 11 , wherein the base frequency of the first signal and the second signal is between 100 KHz and 500 KHz.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2023
From: SIFF, BRADFORD; CARTER, JOHN
To: BIOWAVE CORPORATION
Reel/Frame 064449/0558 →
Continuity (3)
Continuation 16661728 · Oct 23, 2019
Provisional Application 62749233 · Oct 23, 2018
Related Publication 20230248970A1 · Aug 10, 2023
References Cited (29)
US 5269304A · Matthews · 1993 [cited by applicant]
US 5397338A · Grey et al. · 1995 [cited by applicant]
US 6584358B2 · Carter et al. · 2003 [cited by applicant]
US 6760627B2 · Carter et al. · 2004 [cited by applicant]
US 6792315B2 · Carter et al. · 2004 [cited by applicant]
US 6853863B2 · Carter et al. · 2005 [cited by applicant]
US 7013179B2 · Carter et al. · 2006 [cited by applicant]
US 7130696B2 · Carter et al. · 2006 [cited by applicant]
US 11633594B2 · Siff et al. · 2023 [cited by applicant]
US 11813450B2 · Siff · 2023 [cited by applicant]
US 20050033381A1 · Carter et al. · 2005 [cited by applicant]
US 20050187591A1 · Carter et al. · 2005 [cited by applicant]
US 20070016268A1 · Carter et al. · 2007 [cited by applicant]
US 20080033492A1 · Siff et al. · 2008 [cited by applicant]
US 20080097530A1 · Muccio et al. · 2008 [cited by applicant]
US 20100234919A1 · Minogue et al. · 2010 [cited by applicant]
US 20110319947A1 · Chun · 2011 [cited by examiner]
US 20120172940A1 · Wahls et al. · 2012 [cited by applicant]
US 20130268038A1 · Bikson et al. · 2013 [cited by applicant]
US 20130282095A1 · Mignolet et al. · 2013 [cited by applicant]
US 20160121099A1 · Kiani et al. · 2016 [cited by applicant]
US 20180249767A1 · Begriche et al. · 2018 [cited by applicant]
US 20200121925A1 · Siff et al. · 2020 [cited by applicant]
US 20210178158A1 · Siff · 2021 [cited by applicant]
WO 2020072128A1 · 2020 [cited by applicant]
WO 2022182546A1 · 2022 [cited by applicant]
International Search Report and Written Opinion of PCT/US2022/016413 Issued by the International Searching Authority; May 12, 2022, Entire Document. [cited by applicant]
PCT Notification Concerning Transmittal of International Preliminary Report on Patentability issued by the International Bureau on Sep. 7, 2023 for PCT International Application No. PCT/US2022/016413, Entire Document. [cited by applicant]
Supplementary European Search Report issued by the European Patent Office on Nov. 18, 2024 for European Patent Application No. 22760216 (8 pages). [cited by applicant]